# INTerpath-002: HCP commentary report

> 36 verified statements (8 from clinicians verified by NPI or staff page) from 19 commentary sources · 6 findings · updated Oct 29, 2026

## Report

- Trial: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
- NCT ID: NCT06077760
- Registry: https://clinicaltrials.gov/study/NCT06077760
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: pembrolizumab
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: dba33071814758551189528e916a4745cdbb820259737febb9446b724081e7bc

## Counts

- HCP commentary sources screened: 50
- Sources cited by verified statements: 20
- Verified statements: 36
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 8
- Findings: 6
- People found in screened sources: 14
- Voices cited: 11
- Cited voices identity-verified: 6
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

INTerpath-002 asks whether adding a personalized vaccine to pembrolizumab after complete resection of stage II, IIIA or IIIB (N2) NSCLC improves disease-free survival. In the sources reviewed for this edition, an X poster questions its positioning against neoadjuvant therapy. One medical oncologist expresses enthusiasm for personalization, while another X poster raises administration-burden concerns. Whether the strategy meaningfully improves cure remains open for that oncologist.

## Open Medical Affairs question

What evidence would establish a meaningful improvement in cure and clarify the strategy’s place alongside perioperative options?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Enthusiasm for personalization remains conditional on improving cure in resected NSCLC
- F2. The postoperative add-on strategy is distinct from the question of outperforming neoadjuvant therapy
- F3. Conceptual promise and evidentiary credibility attract different challenges
- F4. Cross-center recruitment and infusion-chair burden are practical discussion points
- F5. An exploratory combination question explicitly sets staging aside
- F6. Wider platform and market comparisons should not be read as clinical alternatives for the trial population

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 7 | 5 | 4 | recorded | 3 |
| F2 | 10 | 6 | 6 | 4 | recorded | 3 |
| F3 | 3 | 3 | 2 | 3 | recorded | 3 |
| F4 | 6 | 3 | 3 | 2 | none recorded | 4 |
| F5 | 1 | 1 | 1 | 1 | none recorded | 3 |
| F6 | 7 | 4 | 4 | 3 | none recorded | 6 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 2 | 0 | 0 | 2 | 9 | 2 | 4 posts and articles, 1 registry | yes |
| F2 | 4 | 1 | 0 | 0 | 5 | 14 | 5 | 4 posts and articles, 1 podcast or video, 1 registry | yes |
| F3 | 1 | 2 | 0 | 0 | 0 | 3 | 2 | 2 posts and articles | yes |
| F4 | 1 | 0 | 0 | 1 | 4 | 8 | 1 | 2 posts and articles, 1 podcast or video | yes |
| F5 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 post or article | yes |
| F6 | 1 | 0 | 0 | 1 | 5 | 10 | 2 | 4 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Disease- Free Survival (DFS): no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (2 shared claims), F2 (5 shared claims), F4 (1 shared claims)
- The comparison: F2 (6 shared claims), F4 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (1 shared claims), F4 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. The postoperative add-on strategy is distinct from the question of outperforming neoadjuvant therapy

An X thread identifies the treatment combination under discussion as an mRNA cancer vaccine with pembrolizumab.

Source: X thread, 2026-09-10.

### F1. Enthusiasm for personalization remains conditional on improving cure in resected NSCLC

An X post by a medical oncologist describes the phase III study population as patients with surgically resected stage II–IIIB NSCLC.

Source: X thread, 2026-05-22.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 36 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 20 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

9 discussed · 3 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Disease- Free Survival (DFS) | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 9 | 7 |
| The comparison | discussed | 8 | 6 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 4 | 5 |
| Cross-tumor rationale and the unresolved cure question | discussed | 6 | 3 |
| Comparative benefit versus neoadjuvant treatment | discussed | 3 | 2 |
| Conceptual relevance and evidentiary credibility | discussed | 3 | 2 |
| Administration burden and cross-center recruitment | discussed | 6 | 3 |
| An unspecified ICI-like drug combined with mRNA-4157 | discussed | 1 | 1 |
| Personalized-vaccine comparisons with CAN-2409 and TIL approaches | discussed | 7 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 44 | 17 |
| Bluesky threads | 4 | 0 |
| YouTube | 2 | 2 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-10-11 to 2026-10-25
- Cited window: 2023-12-12 to 2026-10-25
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
- Registry: NCT06077760 (https://clinicaltrials.gov/study/NCT06077760)
- Study IDs: V940-002 · 2023-504923-20-00 (EU CT) · U1111-1290-3969 (UTN) · jRCT2061240063 (jRCT) · PHRR240705-007252 (PHRR)
- Sponsor: Merck Sharp & Dohme LLC
- Collaborators: ModernaTX, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 868 (estimated)
- Start: 2023-12-06 (actual)
- Primary completion: 2030-06-25 (estimated)
- Primary endpoint: Disease- Free Survival (DFS) (Up to ~78 months)
- Intervention: Intismeran autogene (biological)
- Intervention: Pembrolizumab (biological)
- Intervention: Placebo (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, repeated posts and source counts do not establish additional independent clinical voices or consensus.
- No full protocol, exact-trial results publication or exact product label was available in the reviewed material. The report cannot provide a complete methods, regulatory, efficacy or safety assessment.
- Melanoma findings, including first impressions of leaked data, are used by contributors as rationale or context. They are not INTerpath-002 outcomes, and uncertainty from the INTerpath-009 residual-disease setting is not a direct assessment of this trial.
- Some contributors have no confirmed clinical role. Descriptions such as MD or surgical oncologist are attributed source descriptions where noted, not independently confirmed credentials; confirmed personal identity does not increase the certainty of an opinion.
- Enrollment is described only at the time of the relevant recording, without an identified speaker. It should not be treated as confirmation of current trial status.
- Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist capacity and access barriers in resectable non-small-cell lung cancer.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition, corrected 2026-10-29
  - Correction 2026-10-29: Corrected to match the delivered report: per-finding counts; the limitations; the sample findings; source quotations and links in the paid report. The trial's name is spelled as its investigators write it, “INTerpath-002” (NCT06077760), outside quotations (was “Interpath”). The trial's registration date is now stated.

Last checked for new commentary 2026-10-29. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (36 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (6 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/interpath-002-nct06077760
- Agents: POST https://www.erudio.com/api/orders with {"report": "interpath-002-nct06077760", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=interpath-002-06077760

## Cite

Erudio Health. INTerpath-002 (NCT06077760): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/interpath-002-nct06077760

## Machine access

- JSON: https://www.erudio.com/reports/interpath-002-nct06077760.json
- Markdown: https://www.erudio.com/reports/interpath-002-nct06077760.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "interpath-002-06077760"}`